SHYNDEC(SH:600420) 智通财经网·2026-01-12 10:17Group 1 - The core point of the article is that China National Pharmaceutical Group Modern (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd. (referred to as Weichida), received approval from the National Medical Products Administration for a supplemental application for the injection of Piperacillin Sodium, which includes a new 1.0g specification and the approval of 0.5g, 1.0g, and 2.0g formulations through the consistency evaluation of generic drug quality and efficacy [1] Group 2 - The injection of Piperacillin Sodium is primarily used for treating infections caused by sensitive Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species, including sepsis, upper urinary tract and complicated urinary tract infections, respiratory infections, biliary infections, abdominal infections, pelvic infections, as well as skin and soft tissue infections [1] - Piperacillin can also be used in combination with aminoglycosides for infections in patients with neutropenic immunodeficiency [1]